Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma

Abstract

Background (or purpose)

Nivolumab has been shown to be effective for the treatment of second-line mRCC. The present study has investigated the effectiveness and safety of nivolumab in real-world Eastern Spanish patients with advanced mRCC at TKI progression.

Patients and methods

A retrospective review of mRCC patients treated with nivolumab as a second-line treatment was performed. Analyzed variables included age, sex, ECOG (quality of life scale designed by the Eastern Cooperative Oncology Group), histology, nephrectomy, location of metastases, number of metastasis locations, previous treatments, analytical data from the standard blood count and biochemistry, and response to treatment.

Results

98 patients from 18 sites in Spain were retrospectively reviewed. The majority of patients were male (75%), had ECOG 0–1 (90.6%), had no brain metastasis (91.4%), had undergone one prior systemic regimen (94.3%), and were current/former smokers (97.1%). Fourteen patients (13.1%) had non-clear cell histology, seven (7.1%) had poor-IMDC prognostic group characteristics, 13 patients (13.1%) had liver metastasis and 35 (35.7%) had bone lesions. All patients received prior systemic therapy (63.3% sunitinib, 34.7% pazopanib). During the study, a median of eight doses of nivolumab was given (range 2–62) and 11 patients received more than 12 doses. Eleven patients (11.2%) received nivolumab as a third or fourth line of treatment. Median duration of therapy was 3.6 months (range 0.5–29.3). Confirmed response rate was 25%. Median progression free survival was 7.8 months (range 1.2–12.1). Median overall survival was 16.3 months (range 1.7–29.3). After discontinuation of treatment, 27.58% of the patients received subsequent systemic cancer therapy. Side effects were mostly grade 1–2 (7.2% had hypothyroidism and 6.2% liver toxicity, 4% had nephritis and 2% hypophysitis). Two cases of grade 3–4 adverse events (2%) were reported.

Conclusion

Benefit/risk profile of nivolumab in Eastern-Spanish real-world population with mRCC after tyrosine-kinase inhibitors was consistent with prior real-life studies reported as well as pivotal study.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

  2. 2.

    Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;22(370):2103–11.

  3. 3.

    Motzer RJ, Hutson TE, Tomczack P, Michaelson MD, Bukowski RM, et al. Sunitinib versus interferón alfa in metastatic renal-cell carcinoma. N Engl J Med. 2011;356(2):115–24.

  4. 4.

    Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.

  5. 5.

    Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.

  6. 6.

    Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.

  7. 7.

    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

  8. 8.

    Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al. Nivolumab versus everolimus in renal cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

  9. 9.

    Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;19:1814–23.

  10. 10.

    Escudier B, Sharma P, McDermott D, George S, Hammers H, et al. Checkmate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72:932–71.

  11. 11.

    De Giorgi U, Carteni G, Giannarelli D, Basso U, Galli L, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-word results from and expanded access program). BJU Int. 2019;123(1):98–105.

  12. 12.

    Albiges L, Negrier S, Dalban C, et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC) Results from the NIVOREN GETUG-AFU 26 study. J Clin Oncol. 2018;37:5.

  13. 13.

    Nieder C, Syed MA, Dalhaugh A, Pawinski A, Norum J. Elegibility for a phase 3 clinical trials os systemic therapy in real-word patients with metastatic renal cell cancer managed in a rural region. Med Oncol. 2017;34:9.

  14. 14.

    Yip S, Wells C, Moreira RB, Wong A, Srinivas S, et al. Real word experience of immune-oncology agents in metastatic renal cell carcinoma Results from the IMDC. J Clin Oncol. 2017;35:6.

  15. 15.

    Sattar J, Kartolo A, Hopman WM, Lakoff JM, Baetz T. The efficacy and toxicity of immune checkpoint inhibitors in a real-word older patient population. J Geriatr Oncol. 2018;10:411–4.

  16. 16.

    Grimm M, Grünwald V, Bedke J. Real world evidence in renal cell carcinoma: a national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA). Oncol Res Treat. 2018;41(Supplement):1.

  17. 17.

    Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in Checkmate 025. Eur Urol. 2017;72(3):368–76.

Download references

Funding

This study has received no funding.

Author information

All authors contributed to the study conception and design. Material preparation and data collection were performed by all of them. Analysis of data was performed by the corresponding author. The first draft of the manuscript was written by MJJF, and all authors commented on previous and final versions of the manuscript. All authors read and approval the final manuscript.

Correspondence to J.-F. M. José.

Ethics declarations

Conflict of interest

No organization has sponsored the research. The authors do not present a continuous financial relationship with the laboratory responsible for the drug referred to in the article. However, some of them have declared they have received fees for specific and punctual local talks (Dr Climent, Dra Marin, Dra Chirivella, Dr Sureda, Dr Ros, and Dr Juan).

Ethical approval

This study has been approved by the appropriate ethics committee and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

All alive persons gave their informed consent prior to their inclusion in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

José, J.M., Jose, M., Silverio, R. et al. Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma. Clin Transl Oncol (2020). https://doi.org/10.1007/s12094-020-02288-9

Download citation

Keywords

  • Nivolumab
  • Renal
  • Cancer
  • Spanish
  • Experience